[A22-75] Pembrolizumab (colorectal cancer) – Benefit assessment according to § 35a SGB V
Last updated 02.11.2022
Commission awarded on 21.07.2022 by the Federal Joint Committee (G-BA).
Adults with unresectable or metastatic microsatellite instability high or mismatch repair deficient colorectal cancer; after previous fluoropyrimidine-based combination therapy
Added benefit not proven
After completion of the assessment by IQWiG the Federal Joint Committee (G-BA) conducts a commenting procedure. This may provide supplementary information and as a result lead to a modified benefit assessment. Further information and the decision on the early benefit assessment can be found on the relevant page of the G-BA website.